We serve 2-bromo-N-methyl-N-(4-nitrophenyl)acetamide CAS:23543-31-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: 2-bromo-N-methyl-N-(4-nitrophenyl)acetamide
CAS.NO: 23543-31-9
Synonyms:
N-bromoacetyl-N-methyl-4-nitro-aniline
N-(2-bromomethylcarbonyl)-N-methyl-4-nitroaniline
2-Brom-4'-nitro-N-methylacetanilid
N-methyl-4-nitro-
Molecular Formula: C9H9BrN2O3
Molecular Weight: 273.08300
Physical and Chemical Properties:
Density: 1.6g/cm3
Boiling point: 387.2 °C at 760 mmHg
Melting point: /
Flash point:188.0°C
Refractive index: 1.636
Specification:
Appearance: white solid
Purity:≥99%
Packing:
25kg cardboard drum or according to customer specified requirements
Storage: Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Nintedanib esylate CAS:656247-18-6
Intermediates of Nintedanib CAS:656247-17-5
Contact us for information like 2-bromo-N-methyl-N-(4-nitrophenyl)acetamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-methyl-4-nitro- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(2-bromomethylcarbonyl)-N-methyl-4-nitroaniline Use and application,2-Brom-4′-nitro-N-methylacetanilid technical grade,usp/ep/jp grade.
Related News: There are also new directives that relate to US citizens.3,5-Dimethylbenzoic acid manufacturer Pharmaceutical intermediates and APIs belong to the fine chemical industry.4-Aminopiperidine supplier We are pleased that he is doing well,” said BPHC Executive Director Rita Nieves. “Right now, we are not asking Boston residents to do anything differently.2-Hydroxy-4-methoxybenzophenone vendor We are pleased that he is doing well,” said BPHC Executive Director Rita Nieves. “Right now, we are not asking Boston residents to do anything differently.”This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.
